Grace Therapeutics, Inc. filings document material events, operating updates and governance matters for a late-stage biopharma company advancing GTx-104. Form 8-K disclosures cover quarterly results, corporate presentations, the GTx-104 New Drug Application, the FDA Complete Response Letter, and the chemistry, manufacturing and controls and non-clinical subjects cited in that regulatory correspondence.
The filing record also includes disclosures on patent protection for “Nimodipine Parenteral Administration,” exercises and expirations of common warrants issued in private placements, exhibit-based press releases, and amendments to executive letter agreements and compensation arrangements.
Grace Therapeutics, Inc. (GRCE) reported that director Kavuru Vimal received a grant of stock options for 12,200 shares of common stock on September 17, 2026. The options carry an exercise price of $2.13 per share and expire on September 16, 2036.
According to the grant terms, 50% of the options vest immediately on the grant date, with the remaining 50% vesting in substantially equal monthly installments over a 12-month period, subject to Mr. Vimal’s continuous service. Following this award, he holds 12,200 options directly.
Grace Therapeutics, Inc. (GRCE) reported that director Kottayil George received a stock option grant covering 12,200 shares of common stock on September 17, 2026 at an exercise price of $2.13 per share. The option expires on September 16, 2036.
According to the vesting terms, 50% of the option vests on the grant date and the remaining 50% vests in substantially equal monthly installments over a 12‑month period, subject to his continuous service on each vesting date. No Rule 10b5‑1 trading plan is reported for this award.
Grace Therapeutics, Inc. (GRCE) reported the results of its September 17, 2026 Annual Meeting of Stockholders, where stockholders representing 9,973,325 shares, or 61.28% of the 16,274,026 shares outstanding as of July 20, 2026, were present or represented by proxy.
All five director nominees (Vimal Kavuru, A. Brian Davis, Prashant Kohli, S. George Kottayil and Edward Neugeboren) were elected, each receiving about 6.0 million votes for and approximately 3.93 million broker non-votes. Stockholders approved, on an advisory basis, named executive officer compensation, with 5,740,999 votes for, and ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 9,878,292 votes for.
In a separate advisory vote on the frequency of future say‑on‑pay votes, stockholders expressed a preference for an annual vote, with 5,772,652 votes for “1 year,” and the Board determined to include an advisory vote on executive compensation in its proxy materials every year until the next required frequency vote.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., a ten percent owner, indirectly purchased additional common stock through Opaleye, L.P. The fund bought 9,393 shares on September 8, 2026 at a weighted average price of $2.0972 per share and 5,836 shares on September 9, 2026 at a weighted average price of $2.0899 per share in open-market or private transactions. The prices reflect ranges of $2.095–$2.10 and $2.085–$2.09, respectively, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest; no Rule 10b5-1 trading plan is reported.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli purchased 100,000 shares of common stock on September 9, 2026 in an open-market or private transaction at $2.14 per share. Following this purchase, he directly holds 121,357 shares of Grace Therapeutics common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Grace Therapeutics, Inc. (GRCE) reported that officer Kumar Amresh, VP Program Management, received a grant of stock options for 35,760 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27, with post-grant holdings of 35,760 options.
According to the award terms, the options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting over the following 11 quarters, subject to Mr. Amresh’s continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Medical Officer Macdonald R. Loch received a grant of 54,690 stock options on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27. They vest quarterly over three years, with 1/12 vesting immediately and the remaining 11/12 in equal quarterly installments, subject to continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli received a grant of 267,160 stock options on 2026-08-28. The options have an exercise price of $2.12 per share, expire on 2036-08-27, and relate to 267,160 shares of common stock. According to the vesting terms, 1/12 of the options vested immediately on the grant date and the remaining 11/12 vest in substantially equal quarterly installments over the following 11 quarters, subject to his continuous service.
Grace Therapeutics, Inc. (GRCE) reported that its Principal Financial Officer, Robert J. DelAversano, received a grant of stock options covering 33,660 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27.
These options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting equally over the following 11 quarters, subject to his continuous service. Following this award, he holds 33,660 derivative securities of this type directly.